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Introduction: The aim of this randomized-controlled clinical trial was to assess the effect 
of intraligamentary (PDL) injection of dexamethasone on onset and severity of post-
treatment pain in patients with symptomatic irreversible pulpitis. Methods and Materials: 
A total number of 60 volunteers were included according to the inclusion criteria and were 
assigned to three groups (n=20). After administration of local anesthesia and before 
treatment, group 1 (control) PDL injection was done with syringe containing empty 
cartridge, while in groups 2 and 3 the PDL injection was done with 0.2 mL of 2% lidocaine 
or dexamethasone (8 mg/2 mL), respectively. Immediately after endodontic treatment 
patients were requested to mark their level of pain on a visual analogue scale (VAS) during 
the next 48 h (on 6, 12, 24 and 48-h intervals). They were also asked to mention whether 
analgesics were taken and its dosage. Considering the 0-170 markings on the VAS ruler, 
the level of pain was scored as follows: score 0 (mild pain; 0-56), score 1 (moderate pain; 
57-113) and score 3 (severe pain; 114-170). The data were analyzed using the Kruskal-Wallis 
and the Chi-square tests and the level of significance was set at 0.05. Results: After 6 and 
12 h, group 1 and group 3 had the highest and lowest pain values, respectively (P<0.01 and 
P<0.001 for 6 and 12 h, respectively). However, after 24 and 48 h the difference in the pain 
was not significant between groups 1 and 2 (P<0.6) but group 3 had lower pain levels 
(P<0.01 and P<0.8 for 24 and 48 h, respectively). Conclusion: Pretreatment PDL injection 
of dexamethasone can significantly reduce the post-treatment endodontic pain in patients 
with symptomatic irreversible pulpitis. 
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Introduction 
anagement of endodontic pain has a positive impact on 
reducing fear and anxiety of endodontic patients [1, 2]. 
Endodontic pain management encompasses all aspects of 
treatment; preoperative pain control includes accurate diagnosis 
and anxiety reduction; while intraoperative pain control mainly 
depends on effective local anesthetic/operative techniques. 
Comprehensive knowledge of local anesthetic solutions and 
their in-time proper use are necessary for pain-free treatment 
experience of endodontic patients [1]. However, management of 
postoperative pain may be as important if not superior. Most of 
the endodontic patients believe that pain perception subsequent 
to endodontic treatment of a tooth is unavoidable, yet several 
clinical trials indicated that postoperative pain occurs not in all 
endodontic patients [3, 4]. Control of post-endodontic pain can 
M
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involve a variety of techniques and pharmacologic agents [1, 3]. 
Ineffectiveness of local anesthesia in symptomatic teeth with 
irreversible pulpitis has always been a matter of complexity for 
both patient and the clinician. Various mechanisms have been 
proposed to explain this phenomenon including the 
sensitization or activation of nociceptors by inflammation-
released cytokines (such as prostaglandins) and associated 
central mechanisms [5, 6], etc. Prostaglandins which are 
terminal products of arachidonic acid cyclooxygenase (COX) 
pathway metabolism [7]; can sensitize the nociceptors to 
bradykinin and histamine factors as the main agents of 
inflammatory soup in inflamed pulps [2, 5, 7].  
On the other hand, the endodontic treatment by itself can 
cause the release of inflammatory mediators (e.g. 
prostaglandins, leukotrienes, bradykinin, platelet-activating 
factor and substance P) into the surrounding periapical tissues 
[6]. As a result, pain fibers are directly stimulated (by bradykinin 
for instance) or sensitized (by prostaglandins) in situ [8]. In 
addition, the vascular dilation and increased permeability as a 
consequence of periradicular inflammation, causes edema and 
increased interstitial tissue response [6]. 
Considering the role of prostaglandins on endodontic pain, a 
possible strategy for reduction of post-operative endodontic pain 
might be the local use of an anti-inflammatory agents adjacent to 
the inflamed tooth to decrease the production of inflammatory 
mediators [1, 6] and improve the efficacy of local anesthetics. 
Dexamethasone is a potent glucocorticoid with anti-
inflammatory efficacy 25 times more than that of hydrocortisone 
[1]. Mehrvarzfar et al. [6] have shown that supra periosteal 
infiltration of dexamethasone can reduce or even prevent 
postoperative pain in patients with irreversible pulpitis. 
The purpose of this double-blind placebo controlled clinical 
trial was to compare the effect of intra-ligamentary injection of 
dexamethasone (8 mg/2 mL) and 2% lidocaine with 1:80000 
epinephrine on postoperative pain of endodontic patients with 
symptomatic irreversible pulpitis. The null hypothesis was that 
there is no difference in the incidence of post-endodontic pain in 
patients receiving intra-ligamentary injection of dexamethasone 
and 2% lidocaine during endodontic treatment. 
Materials and Methods 
The study protocol was evaluated and approved by Human 
Ethics Committee of Azad University, Dental Branch, Tehran, 
Iran. After performing a pilot study on 6 patients, using sample 
size calculation menu of Minitab, the minimum sample size for 
each group was estimated to be 20 (total sample size=60).  
The inclusion criteria for patient selection were as follows: age 
range of 18-65 years, systemically healthy patient (ASA I or II), 
and necessity of endodontic treatment on maxillary/mandibular 
first or second vital molars, clinical manifestations of 
symptomatic irreversible pulpitis, absence of widening in the 
periodontal ligament (PDL) and periapical lucency of 
endodontic origin on parallel periapical radiographies. Pulpal 
status was determined after testing with EndoIce frozen gas 
(Coltene/Whaledent, Inc., Mahwah, NJ, USA) and electric 
pulp tester (Analytic Technology, Redmond, WA, USA). An 
uncomfortable sensation or pain that had the tendency to 
linger as a dull ache after termination of the stimulus was 
considered abnormal [9] and a pain score of ≥56 degrees 
(moderate to severe) on numeric visual analogue scale (VAS) 
indicated by the patient were necessary inclusion criteria [10]. 
Likewise the exclusion criteria included: systematic 
complexity (ASA III, IV, and V), pregnancy and nursing, age 
less than 18 and more than 65, any contraindication or 
sensitivity to corticosteroids, gastrointestinal disorders, 
hemostatic disorders or anti-coagulant therapy during the last 
month, consumption of opioid or non-opioid analgesics, 
corticosteroids, three cyclic anti-depressants and etc. during 
the last 12 h before treatment. 
Volunteers who met the criteria had to sign a fully 
informed consent. The demographic data of patients were 
meticulously recorded. The endodontic treatment started with 
injection of 1.8 mL of 2% lidocaine containing 1:80000 
epinephrine (Darupakhsh, Tehran, Iran) for local anesthesia 
(buccal infiltration for maxillary molars and inferior alveolar 
nerve block for mandibular molars). The depth of anesthesia 
was checked twice with electric pulp tester in 15-min intervals. 
Should two negative responses were elicited via a maximum 
power of electrical impulses (power of 80) the case was 
condemned as failed anesthesia. For cases with unsuccessful 
anesthesia the injection was repeated.  
Then the patients were randomly divided into 3 groups 
(n=20). In group 1 the operator pretended to perform a PDL 
injection with an empty cartridge using a short 20-mm 30-gauge 
needle set on an intra-ligamental syringe (Anthogyr 
Manufacturing, Sallanches, France). The injection needle only 
touched the tissues without any penetration. In group 2, before 
the onset of treatment 0.2 mL of 2% lidocaine containing 
1:80000 epinephrine was injected into PDL at mesiobuccal and 
distobuccal corners of the tooth with the needle entering the 
PDL with 45 degrees inclination and the piston was discarded 
after feeling pressure against injection with the same syringe and 
needle size. In group 3, PDL injection was performed using 0.2 
mL of dexamethasone (8 mg/2 mL, Darupakhsh, Tehran, Iran) 
with similar conditions and devices. The solutions were 
prepared by another blinded operator and the treatment process 
including all injections were done by an independent 
endodontist. To establish a double blinded design, neither the 
patient nor the practitioner were aware of the injection solution. 
After tooth isolation with rubber-dam and preparation of 
the access cavity, root canal treatment was done using hand K-
files (Dentsply Maillefer, Ballaigues, Switzerland) with step-
back technique. The least apical size was set at #30 and apical 
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patency was maintained for all teeth. The canals were irrigated 
with normal saline and obturated with lateral condensation of 
gutta-percha and sealer (AH-26, Dentsply, Tulsa Dental, Tulsa, 
OK, USA). After termination of treatment the access cavity was 
restored with temporary restoration (Cavit, ESPE-Premier, 
Norristown, PA, USA) and the occlusion and proximal 
integrity was meticulously checked to prevent future pain. 
Before dismissal the patients were briefed about filling of the 
pain questioner after 6, 12, 24 and 48 h and they were also 
contacted on the due time. Patients were given a non-numeric 
VAS ruler which had signs and a similar numerated ruler was 
kept by the operator who had to correlate the VAS pain signs 
marked by the patient to the corresponding scores from 0 to 
170. The level of pain was scored as follows: score 0 (mild pain; 
0-56), score 1 (moderate pain; 57-113) and score 3 (severe pain; 
114-170). The patients were also asked to record the type and 
dosage of analgesics consumption if needed to reduce their 
post-operative pain. 
The data were analyzed using the Kruskal-Wallis and the 
Chi-square tests. The level of significance was set at 0.05. 
Results 
A total of 60 volunteers (30 in each group) met the criteria and 
were found eligible for this study. The patient distribution into 
different test groups was not significantly different regarding 
gender, age, the level of pretreatment pain, the type of tooth and 
presence/absence of acute apical periodontitis (P<0.2) (Table 1). 
Before treatment the highest and lowest level of post-endodontic 
pain was found in group 1 (placebo) (106.4±35.4) and group 2 
(lidocaine) (97.8±36.07), respectively. However the Kruskal-
Wallis test indicated no significant differences (P<0.4). 
After 6 h the highest and lowest level of post-treatment pain 
were found in placebo (80±44) and dexamethasone groups 
(dexamethasone) (35.25±17.47), respectively. The main value of 
pain significantly decreased in all three groups (P<0.05). The 
amount of pain reduction was 65%, 48% and 25% in 
dexamethasone, lidocaine and placebo groups, respectively, and 
this reduction was statistically significant between all groups and 
also in two-by-two comparison (P<0.01). The highest amount of 
analgesic consumption was in placebo (70%), lidocaine (50%) 
and dexamethasone (40%) groups, respectively. The Chi-square 
test did not reveal a significant difference in this regard. 
After 12 h, similarly the lowest amount of pain level was 
found in dexamethasone group while the placebo group had the 
highest pain (P<0.01). Two-by-two comparison revealed that 
the placebo and lidocaine group and dexamethasone and 
placebo group were significantly different (P<0.01 and P<0.001, 
respectively). There was no report of moderate and severe pain 
in dexamethasone group. The pattern of taking analgesics 
followed the similar manner in descending order: placebo 
(60%), lidocaine (25%) and dexamethasone (25%). 
The Chi-square test showed a significant difference between 
the placebo and other two groups. After 24 h, although the 
placebo group maintained the highest level of pain perception, 
the difference was not significant with others (P<0.6) and the 
two-by-two comparison did not show a significant difference 
between lidocaine and placebo groups, either (P<0.6). 
Table 1. Demographic data of patients in different groups 
Groups  Age (y) 
Gender N (%) 
Pretreatment pain mean (SD) 
Tooth N (%) AAP N (%) 
Male Female First molar Second molar Yes No 
Placebo 32 (4.6) 9 (45) 11 (55) 106.4 (35.4) 14 (70) 6 (30) 8 (40) 12 (60) 
Lidocaine 26.1 (9.8) 10 (50) 10 (50) 97.8 (36.07) 11 (55) 9 (45) 8 (40) 12 (60) 
Dexamethasone 30.35 (4.2) 8 (40) 12 (60) 100.6 (29.61) 14 (70) 6 (30) 12 (60) 8 (40) 
P-value 0.8 0.7 0.4 0.2 0.2 
Table 2. Mean (SD) of pain level in different groups before and after treatment 
Groups  Before treatment After 6 h After 12 h After 24 h 
Placebo 106.4 (35.4) 80 (44.6) 45 (30.3) 14 (12.8) 
Lidocaine 97.8 (036.07) 50.45 (26.9) 30.05 (17.06) 11.85 (10.76) 
Dexamethasone 100.6 (29.61) 35.25 (17.47) 12.3 (35.4) 7.7 (9.91) 
P-value 0.4 0.05 0.01 0.6 
Table 3. Analgesic consumption after treatment in different groups 
Groups  
After 6 h After 12 h After 24 h After 48 h 
Yes No Yes No Yes No Yes No 
Placebo 6 (30) 14 (70) 8 (40) 12 (60) 18 (90) 2 (10) 0 (0) 0 (0) 
Lidocaine 10 (50) 10 (50) 15 (75) 5 (25) 18 (90) 2 (10) 0 (0) 0 (0) 
Dexamethasone 12 (60) 8 (40) 15 (75) 5 (25) 19 (95) 1 (5) 0 (0) 0 (0) 
P-value 0.05 0.01 0.6 0.8 
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The patients in dexamethasone group maintained the 
significantly different pain level compared to the placebo 
(P<0.01). The analgesics consumptions were almost similar in 
all groups without significance. 
After 48 h, the highest and lowest pain level were reported 
in placebo and dexamethasone groups, respectively but the 
difference was not significant (P<0.8). There was no report of 
moderate and severe pain in any groups after 24 and 48 h. 
There was no report of analgesic consumption after 48 h 
(Tables 2 and 3). 
Discussion 
This double-blind placebo controlled clinical trial evaluated the 
effect of intraligamentary injection of dexamethasone and 2% 
lidocaine on reduction of postoperative pain in patients with 
irreversible pulpitis using VAS. The VAS score data showed that 
intraligamentary injection of low dose of dexamethasone was 
more effective in reduction of post endodontic pain in 
comparison with lidocaine or placebo group. 
Many endodontic patients believe that post-treatment pain 
is inevitable. The occurrence of a mild postoperative pain is not 
a rare event even when endodontic treatment has followed all 
acceptable standards [11]. According to some studies, 
moderate to severe postoperative pain occurs in only 4-10% of 
all endodontic patients [12], while some other studies reported 
higher incidence (almost 50%) [13]. The causative factors of 
post-treatment pain can be classified as mechanical, chemical, 
and/or microbial insults to the pulp or periradicular tissues, 
which are induced or exacerbated during root canal treatment 
[3]. The intensity of the inflammatory response is directly 
proportional to the intensity of tissue injury [14]. Since the 
tissue/vascular events associated with acute inflammation 
usually result in severe pain, it is conceivable that the greater 
the intensity of the inflammatory reaction the greater the 
intensity of potential pain [5, 7].  
Postoperative pain is usually mild and rarely lasts longer 
than three days. However, some patients will suffer from a 
moderate to severe pain that persists for several days even after 
appropriate endodontic treatment. The persistent pain is often 
attributed to the release of inflammatory mediators such as 
prostaglandins, leukotrienes, bradykinin and serotonin. 
Consequently, peripheral and central hyperalgesia are resulted 
from the activation and sensitization of nociceptors by these 
released mediators, especially prostaglandins [15].  
Various classes of drugs have been studied for the 
management of post-treatment endodontic pain including 
NSAID’s and acetaminophen, opioids and steroids [16, 17]. 
Many studies have proved the effectiveness of preoperative 
administration of NSAIDS in reducing or suppressing the 
post-endodontic pain [18, 19]. Clinicians largely rely on non-
steroidal anti-inflammatory drugs (NSAIDs) to manage post-
endodontic pain [15, 20]. They inhibit the synthesis of 
prostaglandins through retarding the activity of COX1 and 
COX2 enzymes, with the first acting in regulation of normal 
cell activities in stomach, kidneys, endothelial cells, etc. and the 
second appearing in injured and inflamed tissues as an 
inducible enzyme [21]. Although NSAIDs are remarkably 
effective in the management of pain and inflammation, their 
chronic use is limited by a number of adverse effects including 
gastrointestinal bleeding and ulceration, impaired renal 
function and inhibition of platelet aggregation due to 
inhibition of COX1 [17]. 
The results of the current study showed that PDL injection 
of dexamethasone significantly reduced the post-endodontic 
pain levels during the first 12 h postoperatively. Shantiaee et al. 
[22] demonstrated that local infiltration of dexamethasone was 
more effective than morphine to decrease postoperative 
endodontic pain during the first 24 h after operation. 
Dexamethasone is a corticosteroid with strong anti-
inflammatory effects 25 times more than that of endogenic 
cortisol [23]. There are numerous pain-reducing mechanisms 
of steroids mentioned in the literature. Glucocorticoids affect 
the immune response by inhibition of cytokine production, 
specifically interferon γ, granulocyte/monocyte colony 
stimulating factor (GM-CSF), interleukins 1, 2, 3, 6 (IL-1, IL-
2, IL-3, IL-6) and tumor necrosis factor α (TNFα) [23]. Steroids 
can induce intracellular production of many proteins such as 
lipocortin that prevents the synthesis of arachidonic acid and 
thereby reduce the biosynthesis of both cyclooxygenase (COX) 
and lipoxygenase products, including prostaglandins, 
leukotrienes and thromboxane related substances [8]. 
Reduction in pulpal levels of both prostaglandin E2 and IL-8 
in irreversibly inflamed pulps after administration of 
Depomedrol was already reported [24]. Another mechanism of 
action of steroids can be the reduction of bradykinin mediators 
through inducing the synthesis of angiotensin converting 
enzyme (ACE) [23, 25]. Bradykinin activates nociceptors and 
causes the release of substance P, neurokinin A, and calcitonin 
gene-related peptide (CGRP) via activating the B1 and B2 
receptors. The latter receptor mediates the pain in acute 
inflammation while the pain in chronic inflammation 
involves an elevation in number of B1 receptors [26]. 
Reduction of postoperative pain through reducing the 
bradykinin levels by the administration of glucocorticoids 
has been demonstrated in many studies [7, 25, 27]. 
Production of vasocortin that suppresses edema which was 
not suppressed by NSAIDs, is another important mechanism 
of pain suppression by steroids [23]. Glucocorticoids may 
also inhibit neurogenic inflammation by inhibition of the 
release of neuropeptides [28]. 
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It could therefore be assumed that glucocorticoids have 
greater anti-inflammatory and analgesic effects than NSAIDs 
where considering the fact that multiple inflammatory 
mediators are released or produced during pulpal 
inflammation [29]. Thus systemic administration of 
corticosteroid as an alternative strategy to decrease endodontic 
post-treatment pain might be suggested just in those patients 
who present with moderate/severe pain with irreversible 
pulpitis [30]. The point is that almost all of the effects of 
systemically-administered glucocorticoids do not occur 
immediately and may only become apparent after several 
hours or even days after administration [7, 11, 23]. This time 
is required for changes in gene expression and protein 
synthesis induced by such medicine. According to Nobuhara 
et al. [31] the average number of PMNs in the apical and 
middle regions of the PDL space significantly decreased 
following buccal infiltration of dexamethasone, but not until 
48 h postoperatively. However, this study indicated the 
immediate analgesic effect of dexamethasone after 6 and 12 h 
which can be due to mechanisms of action other than those 
including gene expression and protein synthesis. Moreover it 
is important to note that endodontic treatment per se has a 
major effect on reducing post endodontic pain regardless of 
analgesic intervention [23]. 
Conclusion 
The present clinical study represented an effective practical way 
of intraligamentary injection of a very low-dose dexamethasone 
to control moderate to severe post-operative pain in patients 
suffering from symptomatic irreversible pulpitis. Considering 
the adverse or unwanted effects of systemic administration of 
NSAIDs or high doses of corticosteroids, local administration of 
0.2 mL of dexamethasone may seem a safe alternative way for 
pain control. 
Acknowledgment 
The authors wish to thank the staff of ICER.  
Conflict of Interest: ‘None declared’. 
References 
1. Aggarwal V, Singla M, Rizvi A, Miglani S. Comparative evaluation 
of local infiltration of articaine, articaine plus ketorolac, and 
dexamethasone on anesthetic efficacy of inferior alveolar nerve 
block with lidocaine in patients with irreversible pulpitis. J Endod. 
2011;37(4):445-9. 
2. Pochapski MT, Santos FA, de Andrade ED, Sydney GB. Effect of 
pretreatment dexamethasone on postendodontic pain. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod. 2009;108(5):790-5. 
3. Arora M, Sangwan P, Tewari S, Duhan J. Effect of maintaining 
apical patency on endodontic pain in posterior teeth with pulp 
necrosis and apical periodontitis: a randomized controlled trial. Int 
Endod J. 2015. 
4. Arias A, de la Macorra JC, Azabal M, Hidalgo JJ, Peters OA. 
Prospective case controlled clinical study of post-endodontic pain 
after rotary root canal preparation performed by a single operator. 
J Dent. 2015;43(3):389-95. 
5. Nixdorf DR, Moana-Filho EJ, Law AS, McGuire LA, Hodges JS, 
John MT. Frequency of persistent tooth pain after root canal 
therapy: a systematic review and meta-analysis. J Endod. 
2010;36(2):224-30. 
6. Mehrvarzfar P, Shababi B, Sayyad R, Fallahdoost A, Kheradpir K. 
Effect of supraperiosteal injection of dexamethasone on 
postoperative pain. Aust Endod J. 2008;34(1):25-9. 
7. Lin S, Levin L, Emodi O, Abu El-Naaj I, Peled M. Etodolac versus 
dexamethasone effect in reduction of postoperative symptoms 
following surgical endodontic treatment: a double-blind study. 
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2006;101(6):814-7. 
8. Shahi S, Mokhtari H, Rahimi S, Yavari HR, Narimani S, 
Abdolrahimi M, Nezafati S. Effect of premedication with ibuprofen 
and dexamethasone on success rate of inferior alveolar nerve block 
for teeth with asymptomatic irreversible pulpitis: a randomized 
clinical trial. J Endod. 2013;39(2):160-2. 
9. Azimi S, Fazlyab M, Sadri D, Saghiri MA, Khosravanifard B, Asgary 
S. Comparison of pulp response to mineral trioxide aggregate and 
a bioceramic paste in partial pulpotomy of sound human 
premolars: a randomized controlled trial. Int Endod J. 
2014;47(9):873-81. 
10. Torabinejad M, Cymerman JJ, Frankson M, Lemon RR, Maggio JD, 
Schilder H. Effectiveness of various medications on postoperative 
pain following complete instrumentation. J Endod. 1994;20(7):345-
54. 
11. Siqueira J, Barnett F. Interappointment pain: mechanisms, 
diagnosis, and treatment. Endodontic Topics. 2004;7(1):93-109. 
12. Wong AW, Zhang C, Chu CH. A systematic review of nonsurgical 
single-visit versus multiple-visit endodontic treatment. Clin 
Cosmet Investig Dent. 2014;6:45-56. 
13. DiRenzo A, Gresla T, Johnson BR, Rogers M, Tucker D, BeGole EA. 
Postoperative pain after 1- and 2-visit root canal therapy. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod. 2002;93(5):605-10. 
14. Anjaneyulu K, Nivedhitha MS. Influence of calcium hydroxide on 
the post-treatment pain in Endodontics: A systematic review. J 
Conserv Dent. 2014;17(3):200-7. 
15. Arslan H, Topcuoglu HS, Aladag H. Effectiveness of tenoxicam and 
ibuprofen for pain prevention following endodontic therapy in 
comparison to placebo: a randomized double-blind clinical trial. J 
Oral Sci. 2011;53(2):157-61. 
 
IEJ Iranian Endodontic Journal 2016;11(4): 261-266 
266 Mehrvarzfar et al. 
16. Doroschak AM, Bowles WR, Hargreaves KM. Evaluation of the 
combination of flurbiprofen and tramadol for management of 
endodontic pain. J Endod. 1999;25(10):660-3. 
17. Rogers MJ, Johnson BR, Remeikis NA, BeGole EA. Comparison of 
effect of intracanal use of ketorolac tromethamine and 
dexamethasone with oral ibuprofen on post treatment endodontic 
pain. J Endod. 1999;25(5):381-4. 
18. Flath RK, Hicks ML, Dionne RA, Pelleu GB, Jr. Pain suppression 
after pulpectomy with preoperative flurbiprofen. J Endod. 
1987;13(7):339-47. 
19. Gopikrishna V, Parameswaran A. Effectiveness of prophylactic use 
of rofecoxib in comparison with ibuprofen on postendodontic pain. 
J Endod. 2003;29(1):62-4. 
20. Ramazani M, Hamidi MR, Moghaddamnia AA, Ramazani N, 
Zarenejad N. The Prophylactic Effects of Zintoma and Ibuprofen 
on Post-endodontic Pain of Molars with Irreversible Pulpitis: A 
Randomized Clinical Trial. Iran Endod J. 2013;8(3):129-34. 
21. Holt CI, Hutchins MO, Pileggi R. A real time quantitative PCR 
analysis and correlation of COX-1 and COX-2 enzymes in inflamed 
dental pulps following administration of three different NSAIDs. J 
Endod. 2005;31(11):799-804. 
22. Shantiaee Y, Mahjour F, Dianat O. Efficacy comparison of 
periapical infiltration injection of dexamethasone, morphine and 
placebo for postoperative endodontic pain. Int Dent J. 
2012;62(2):74-8. 
23. Marshall JG. Consideration of steroids for endodontic pain. 
Endodontic Topics. 2002;3(1):41-51. 
24. Isett J, Reader A, Gallatin E, Beck M, Padgett D. Effect of an 
intraosseous injection of depo-medrol on pulpal concentrations of 
PGE2 and IL-8 in untreated irreversible pulpitis. J Endod. 
2003;29(4):268-71. 
25. Mohammadi Z. Systemic and local applications of steroids in 
endodontics: an update review. Int Dent J. 2009;59(5):297-304. 
26. Lepinski AM, Hargreaves KM, Goodis HE, Bowles WR. Bradykinin 
levels in dental pulp by microdialysis. J Endod. 2000;26(12):744-7. 
27. Tsesis I, Fuss Z, Lin S, Tilinger G, Peled M. Analysis of 
postoperative symptoms following surgical endodontic treatment. 
Quintessence Int. 2003;34(10):756-60. 
28. Giuliano C, Smalligan RD, Mitchon G, Chua M. Role of 
dexamethasone in the prevention of migraine recurrence in the 
acute care setting: a review. Postgrad Med. 2012;124(3):110-5. 
29. Claffey E, Reader A, Nusstein J, Beck M, Weaver J. Anesthetic 
efficacy of articaine for inferior alveolar nerve blocks in patients 
with irreversible pulpitis. J Endod. 2004;30(8):568-71. 
30. Bramy E, Reader A, Gallatin E, Nist R, Beck M, Weaver J. OR 29 
Pain reduction in symptomatic, necrotic teeth using an 
intraosseous injection of Depo-Medrol. J Endod. 1999;25(4):289. 
31. Nobuhara WK, Carnes DL, Gilles JA. Anti-inflammatory effects of 
dexamethasone on periapical tissues following endodontic 
overinstrumentation. J Endod. 1993;19(10):501-7. 
 
Please cite this paper as: Mehrvarzfar P, Esnashari E, Salmanzadeh R, 
Fazlyab M, Fazlyab M. Effect of Dexamethasone Intraligamentary 
Injection on Post-Endodontic Pain in Patients with Symptomatic 
Irreversible Pulpitis: A Randomized Controlled Clinical Trial. Iran 
Endod J. 2016;11(4):261-6. Doi: 10.22037/iej.2016.2 . 
 
 
 
 
 
 
 
